

NORTHFIELD

LABORATORIES, INC.

1500 SHERMAN AVENUE

SUITE 1000

EVANSTON, IL 60201-1800

CS 171 861-1500

FAX 171 861-0353

www.northfieldlabs.com

0177 6 03 -9 10:08

February 8, 2006

Division of Dockets Management
Food and Drug Administration, Room 1061, (HFA-305)
5630 Fisher's Lane
Rockville, MD 20852

Docket Number 95S-0158 (BB IND #10,719)

RE: BB IND 10,719, POLY-SFH-P INJECTION [Polymerized Human Hemoglobin (Pyridoxylated), PolyHeme[®]], Protocol RTBSE-11-(N): Publicly Disclosed Information

Dear Sir:

Reference is made to our Investigational New Drug Application (IND) for Poly-SFH-P Injection for acute trauma, BB IND #10,719.

In conformance with 21 CFR 312.54(a) and the Draft Guidance for Industry entitled *Exception from Informed Consent Requirements for Emergency Research* (March 30, 2000) which require that Institutional Review Board (IRB) information concerning public disclosure be submitted to this Docket for clinical investigations involving an exception from informed consent [21 CFR 50.24(a)(7)(iii)], we provide documentation for the following site in Dayton, Ohio:

Miami Valley Hospital

IRB: Miami Valley Hospital Institutional Review Board
c/o Clinical Research Center
6th Floor, Weber Building
One Wyoming St.
Dayton, OH 45409

95S-0158


SUP 49

Docket Number 95S-0158
February 8, 2006
Page 2

A copy of this submission is being submitted to BB IND #10,719.

If you have any comments or questions, please contact the undersigned at 847-864-3500.

Sincerely,

A handwritten signature in cursive script, appearing to read "Eva Essig".

Eva Essig, PhD
Vice President, Regulatory Affairs and Quality